Mod­er­na CEO brush­es off US sup­port for IP waiv­er, eyes more than $19B in Covid-19 vac­cine sales in 2021

Mod­er­na is de­fin­i­tive­ly more con­cerned with keep­ing pace with Pfiz­er in the race to vac­ci­nate the world against Covid-19 than it is with Wednes­day’s de­ci­sion from the Biden ad­min­is­tra­tion to back an in­tel­lec­tu­al prop­er­ty waiv­er that aims to in­crease vac­cine sup­plies world­wide.

In its first quar­ter earn­ings call on Thurs­day, Mod­er­na CEO Stéphane Ban­cel shrugged off any sug­ges­tion that the new­ly US-backed in­tel­lec­tu­al prop­er­ty waiv­er would im­pact his com­pa­ny’s vac­cine or bot­tom line. Still, the com­pa­ny’s stock price fell by about 9% in ear­ly morn­ing trad­ing.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN